Close Menu

NEW YORK – Australian diagnostics firm Proteomics International has released results from a recent clinical trial demonstrating the usefulness of its PromarkerD test for identifying diabetes patients at risk of developing chronic kidney disease.

The company is hoping the results will help drive commercialization of the test as it works to drive uptake following receipt this spring of the CE mark for the assay.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.